Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15122014 | 0.86 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C19SRC | |
| SCHEMBL3002688 | 0.82 | POLB (0.52) | SRCCDK2BRAF | |
| SCHEMBL11015321 | 0.81 | SRC (0.56) | SRCCDK2BRAFADORA3ADORA2A | |
| SCHEMBL459414 | 0.80 | ADORA3 (0.68) | SRCCDK2BRAFADORA3ADORA2A | |
| SCHEMBL17372399 | 0.79 | CYP2C19 (0.63) | CYP1A2CYP3A4CYP2D6CYP2C19BRAF | |
| SCHEMBL31012324 | 0.79 | CYP2C19 (0.63) | CYP1A2CYP3A4CYP2D6CYP2C19BRAF | |
| SCHEMBL16146440 | 0.79 | SRC (0.54) | SRCCDK2BRAFADORA3ADORA2A | |
| SCHEMBL3002841 | 0.79 | LMNA (0.46) | SRCCDK2 | |
| SCHEMBL16146744 | 0.78 | BRAF (0.58) | SRCCDK2BRAFADORA3ADORA2A | |
| SCHEMBL16146541 | 0.78 | TNNI3K (0.62) | SRCCDK2BRAFADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-26 | — | — | US | disclosed |
| EP-3233860-B1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIV PALACKEHO (CZ) | 2020-01-29 | — | — | EP | disclosed |
| US-20170342072-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-30 | — | — | US | disclosed |
| EP-3233860-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | Univerzita Palackého V Olomouci (CZ) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095881-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-23 | — | — | WO | disclosed |
| EP-2173173-B1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2013-07-24 | — | — | EP | disclosed |
| US-8222260-B2 | Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives | Univerzita Palackego V Olomouci (CZ) | 2012-07-17 | — | — | US | disclosed |
| US-20100190806-A1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2173173-A2 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009003428-A2 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | TPMT, MTAP, ATIC | CYP1A2 220/4885CYP3A4 388/4885CYP2D6 20/4885 |
| US-20100190806-A1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | DPYD, XDH, APRT | CYP1A2 243/4885CYP3A4 457/4885CYP2D6 39/4885 |
| US-20170342072-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | TPMT, MTAP, ATIC | CYP1A2 220/4885CYP3A4 388/4885CYP2D6 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.